ShareValue scores for BETA.NSE: Valuation 30, Quality 61, Growth 45, Health 47.
BETA.NSENSE
Beta Drugs Ltd.
₹2,069.10
(-3.91%)
BETA.NSENSE
Beta Drugs Ltd.
₹2,069.10(-3.91%)
Loading chart...
Sentiment
Verdicts
Value:Overvalued
Quality:Moderate
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
-6% to 9%
Rating
Trap Risk
Return
-6% to 9%
Valuation
30
Overvalued
Price vs Value
Quality
61
Moderate
Business Strength
Growth
45
Moderate
Revenue & Earnings
Health
47
Moderate
Financial Stability
Momentum
89
Bullish
Price Trend
Company Details
About
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India. Address: SCO-184, Panchkula, India, 134114
Market Cap$21.07B
P/E Ratio50.9
Dividend YieldNone
Sector Rank#2061
Score Analysis
AI Investment Thesis
Data as of:Jul 9, 2026
|Last calculated:Jul 9, 2026